Yong Liu

US Patent:

6495361, Dec 17, 2002

Filed:

Jul 21, 2000

Appl. No.:

09/621579

Inventors:

Paul L. Hermonat - Little Rock AR
Yong Liu - Little Rock AR

Assignee:

University of Arkansas - Little Rock AR

International Classification:

C12N 700

US Classification:

4352351, 435 5, 435 4, 435 71, 435236, 435239, 4351736

Abstract:

The present invention is discloses an improved method of producing infectious papillomavirus in vitro, with a method comprising (a) introducing papillomavirus or papillomavirus DNA or portions thereof necessary for replication, into an epithelial cell; and (b) providing conditions that produce papillomavirus, wherein the conditions comprise not contacting the epithelial cell a fibroblast and does not comprise an organotypic raft culture or a dermal equivalent. The present invention also discloses a papillomavirus infected non-keratinocyte epithelial cell produced by the methods of the present invention. Further, uses of the disclosed method includes detection methods, methods for screening anti-papillomavirus drugs, methods of making recombinant papillomavirus for vaccines and studying the life cycle. Additionally, a method of reducing and assessing the risk of spontaneous abortion is disclosed.

US Patent:

6506600, Jan 14, 2003

Filed:

Mar 22, 2001

Appl. No.:

09/813937

Inventors:

Paul L. Hermonat - Little Rock AR
Michael Mane - Little Rock AR
Yong Liu - Little Rock AR

Assignee:

University of Arkansas - Little Rock AR

International Classification:

C12N 502

US Classification:

435371, 4353201, 435366, 536 231, 536 232

Abstract:

The present invention utilizes AAV as a vector to transfect epithelial cells with an AAV/heterologous gene containing/Neo vector, to form a heterologous protein secreting culture of epithelial cells. This culture is useful for preparing recombinant skin using the organotypic epithelial raft culture system. The sheets of epithelial cells is composed of a stratified sqaumous epithelium composed of a lower layer of immature basal cells and an upper layer of mature keratinized epithelium. The rAAV virus stock prepared without wild type AAV is useful in expressing heterologous protein, however, the maximum production of the heterologous protein was achieved; when the rAAV virus stock contained wild type AAV. This invention discloses that AAV is appropriate for genetically altering skin to secrete new proteins to treat diseases and skin disorders or conditions.

US Patent:

6884605, Apr 26, 2005

Filed:

Aug 9, 2001

Appl. No.:

09/927585

Inventors:

Paul L. Hermonat - Little Rock AR, US
V. Suzanne Klimberg - Little Rock AR, US
Yong Liu - Little Rock AR, US

Assignee:

Board of Trustees of the University of Arkansas - Little Rock AR

International Classification:

C12P019/34

US Classification:

435 911, 435 6, 536 2433

Abstract:

Methods for screening a patient for a cancer wherein the methods comprise detecting an HPV in a biopsy from a patient are disclosed. Also disclosed are compositions and products for screening and for treating cancer in a patient, as well as methods of treating a patient afflicted with a cancer.

US Patent:

20030104575, Jun 5, 2003

Filed:

Jan 13, 2003

Appl. No.:

10/340759

Inventors:

Paul Hermonat - Little Rock AR, US
Michael Mane - Little Rock AR, US
Yong Liu - Little Rock AR, US

Assignee:

University of Arkansas

International Classification:

C12P021/02
C12N005/06
C12N015/861

US Classification:

435/069100, 435/456000, 435/325000

Abstract:

The present invention utilizes AAV as a vector to transfect epithelial cells with an AAV/heterologous gene containing/Neo vector, to form a heterologous protein secreting culture of epithelial cells. This culture is useful for preparing recombinant skin using the organotypic epithelial raft culture system. The sheets of epithelial cells is composed of a stratified sqaumous epithelium composed of a lower layer of immature basal cells and an upper layer of mature keratinized epithelium. The rAAV virus stock prepared without wild type AAV is useful in expressing heterologous protein, however, the maximum production of the heterologous protein was achieved; when the rAAV virus stock contained wild type AAV. This invention discloses that AAV is appropriate for genetically altering skin to secrete new proteins to treat diseases and skin disorders or conditions.

US Patent:

20030157692, Aug 21, 2003

Filed:

Dec 16, 2002

Appl. No.:

10/319532

Inventors:

Paul Hermonat - Little Rock AR, US
Yong Liu - Little Rock AR, US

Assignee:

University of Arkansas

International Classification:

C12N007/00
C12Q001/68
C12P021/06
C12N007/01
C12N007/02
C12N005/00
C12N005/02

US Classification:

435/235100, 435/239000, 435/325000, 435/069100, 435/006000

Abstract:

The present invention is discloses an improved method of producing infectious papillomavirus in vitro, with a method comprising (a) introducing papillomavirus or papillomavirus DNA or portions thereof necessary for replication, into an epithelial cell; and (b) providing conditions that produce papillomavirus, wherein the conditions comprise not contacting the epithelial cell a fibroblast and does not comprise an organotypic raft culture or a dermal equivalent. The present invention also discloses a papillomavirus infected non-keratinocyte epithelial cell produced by the methods of the present invention. Further, uses of the disclosed method includes detection methods, methods for screening anti-papillomavirus drugs, methods of making recombinant papillomavirus for vaccines and studying the life cycle. Additionally, a method of reducing and assessing the risk of spontaneous abortion is disclosed.

US Patent:

20060029943, Feb 9, 2006

Filed:

Dec 6, 2004

Appl. No.:

11/006468

Inventors:

Paul Hermonat - Little Rock AR, US
V. Klimberg - Little Rock AR, US
Yong Liu - Little Rock AR, US

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435006000, 435091200

Abstract:

Methods for screening a patient for a cancer wherein the methods comprise detecting an HPV in a biopsy from a patient are disclosed. Also disclosed are compositions and products for screening and for treating cancer in a patient, as well as methods of treating a patient afflicted with a cancer.

US Patent:

20080199434, Aug 21, 2008

Filed:

Nov 13, 2007

Appl. No.:

11/938992

Inventors:

Jawahar L. Mehta - Little Rock AR, US
Paul L. Hermonat - Little Rock AR, US
Jiawei Chen - Shanghai, CN
Chang-Ping Hu - Little Rock AR, US
Abhijit Dandapat - Galveston TX, US
Yong Liu - Little Rock AR, US

Assignee:

BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS - Little Rock AR

International Classification:

A61K 48/00
A61P 9/10
C12Q 1/68
G01N 33/53
A61K 31/711
A61K 31/7105

US Classification:

424 932, 514 44, 435 6, 435 792

Abstract:

The present invention provides methods and compositions for treating a cardiovascular condition. In particular, provided is a method comprising administering to a subject an agent that increases the level and/or activity of angiotensin II type 2 receptors. Also provided is a method for evaluating the risk of having or developing a cardiovascular condition

US Patent:

20190332067, Oct 31, 2019

Filed:

Apr 29, 2019

Appl. No.:

16/397687

Inventors:

- Knoxville TN, US
- Oak Ridge TN, US
Yong Liu - Knoxville TN, US
Peter Louis Fuhr - Knoxville TN, US
Tom King - Knoxville TN, US
He Yin - Knoxville TN, US
Lingwei Zhan - Knoxville TN, US
Marissa Morales-Rodriguez - Knoxville TN, US
Wenxuan Yao - Knoxville TN, US

International Classification:

G04G 7/00
G04F 5/00

Abstract:

A pulsar based timing synchronization method and system are disclosed. In one example, a method includes receiving, by a pulsar signal receiver device, a pulse signal emitted from one or more celestial objects and processing, by the pulsar signal receiver device, the pulse signal to discipline a local clock to determine an accurate time output. The method also includes generating, by the pulsar signal receiver device, a timing synchronization signal based on the determined accurate time output. The method further includes providing, by the pulsar signal receiver device, the timing synchronization signal to at least one of a local power system device and a timing distribution network server.